FR05C0022I1 - - Google Patents

Info

Publication number
FR05C0022I1
FR05C0022I1 FR05C0022C FR05C0022I1 FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed filed Critical
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 true FR05C0022I1 (OSRAM) 2005-06-10
FR05C0022I2 FR05C0022I2 (OSRAM) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (OSRAM) 1995-03-30 2005-05-09

Country Status (35)

Country Link
US (1) US6417191B1 (OSRAM)
EP (1) EP0817637B1 (OSRAM)
JP (1) JP2954357B2 (OSRAM)
KR (1) KR100542536B1 (OSRAM)
CN (1) CN1103593C (OSRAM)
AP (1) AP652A (OSRAM)
AT (1) ATE220551T1 (OSRAM)
AU (1) AU715213B2 (OSRAM)
BR (3) BR9607851B1 (OSRAM)
CA (1) CA2216634C (OSRAM)
CZ (1) CZ295940B6 (OSRAM)
DE (3) DE69622386T2 (OSRAM)
DK (1) DK0817637T3 (OSRAM)
EA (1) EA000626B3 (OSRAM)
EE (1) EE04047B1 (OSRAM)
ES (1) ES2179193T3 (OSRAM)
FR (1) FR05C0022I2 (OSRAM)
GE (1) GEP20022647B (OSRAM)
HU (1) HU224010B1 (OSRAM)
IL (1) IL117727A (OSRAM)
LU (1) LU91171I2 (OSRAM)
MX (1) MX9707316A (OSRAM)
MY (1) MY115461A (OSRAM)
NL (1) NL300195I2 (OSRAM)
NO (2) NO313787B1 (OSRAM)
NZ (1) NZ306419A (OSRAM)
OA (1) OA10616A (OSRAM)
PL (1) PL187085B1 (OSRAM)
PT (1) PT817637E (OSRAM)
RO (1) RO117995B1 (OSRAM)
SI (1) SI0817637T1 (OSRAM)
SK (1) SK283825B6 (OSRAM)
TR (1) TR199701074T1 (OSRAM)
UA (1) UA60293C2 (OSRAM)
WO (1) WO1996030025A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257708T1 (de) * 1996-06-25 2004-01-15 Glaxo Group Ltd Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
HRP20140379A2 (hr) * 2003-01-14 2014-07-18 Gilead Sciences, Inc. Pripravci i metode za kombiniranu antivirusnu terapiju
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ES2357430T3 (es) 2003-10-24 2011-04-26 Immunaid Pty Ltd Método de terapia.
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2625047A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2435825B8 (en) 2009-05-27 2015-09-02 Biotempus Limited Methods of treating diseases
ME03058B (me) 2010-01-27 2019-01-20 Viiv Healthcare Co Antivirusna terapija
EP3038607A2 (en) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
WO2016023082A1 (en) 2014-08-12 2016-02-18 Monash University Lymph directing prodrugs
CN118063537A (zh) 2015-09-08 2024-05-24 莫纳什大学 定向淋巴的前药
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
EP4100017A4 (en) 2020-02-05 2024-04-10 PureTech LYT, Inc. Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
ATE184787T1 (de) * 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
TR199802703T2 (xx) 1996-06-25 1999-03-22 Glaxo Group Limited HIV tedavisinde Vx478, Zidov�din, ve/veya 1592U89 i�eren kombinasyonlar�n kullan�m�.
ATE257708T1 (de) 1996-06-25 2004-01-15 Glaxo Group Ltd Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
ATE220551T1 (de) 2002-08-15
BR9607851A (pt) 1998-07-21
HU224010B1 (hu) 2005-04-28
UA60293C2 (uk) 2003-10-15
JPH10511682A (ja) 1998-11-10
US6417191B1 (en) 2002-07-09
PL322532A1 (en) 1998-02-02
CA2216634C (en) 2004-07-20
KR19980703420A (ko) 1998-11-05
CA2216634A1 (en) 1996-10-03
AP652A (en) 1998-06-19
NL300195I2 (nl) 2005-11-01
DE122005000029I2 (de) 2006-04-27
PL187085B1 (pl) 2004-05-31
CN1185110A (zh) 1998-06-17
EP0817637B1 (en) 2002-07-17
AU5497296A (en) 1996-10-16
EE04047B1 (et) 2003-06-16
BRPI9612992B1 (pt) 2020-08-04
EA199700203A1 (ru) 1998-02-26
NO2005014I2 (no) 2008-02-11
CN1103593C (zh) 2003-03-26
IL117727A (en) 1999-11-30
DE69622386T2 (de) 2003-02-13
DE122005000029I1 (de) 2005-10-06
TR199701074T1 (xx) 1998-02-21
EA000626B3 (ru) 2016-04-29
JP2954357B2 (ja) 1999-09-27
CZ295940B6 (cs) 2005-12-14
HUP9801571A2 (hu) 1999-01-28
CZ309097A3 (cs) 1998-05-13
LU91171I9 (OSRAM) 2018-12-28
AU715213B2 (en) 2000-01-20
KR100542536B1 (ko) 2006-03-23
EA000626B1 (ru) 1999-12-29
OA10616A (en) 2001-03-15
FR05C0022I2 (OSRAM) 2005-10-21
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
ES2179193T3 (es) 2003-01-16
EE9700240A (et) 1998-04-15
NO974510L (no) 1997-09-29
HK1009401A1 (en) 1999-09-10
LU91171I2 (fr) 2005-07-04
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
MY115461A (en) 2003-06-30
NO974510D0 (no) 1997-09-29
WO1996030025A1 (en) 1996-10-03
BRPI9607851B8 (pt) 2019-11-05
HUP9801571A3 (en) 2001-04-28
DK0817637T3 (da) 2002-11-11
EP0817637A1 (en) 1998-01-14
BR9607851B1 (pt) 2009-01-13
RO117995B1 (ro) 2002-12-30
NO313787B1 (no) 2002-12-02
SK129597A3 (en) 1998-07-08
SI0817637T1 (en) 2002-10-31
NL300195I1 (nl) 2005-08-01
DE69622386D1 (de) 2002-08-22
MX9707316A (es) 1997-11-29
SK283825B6 (sk) 2004-02-03
IL117727A0 (en) 1996-07-23
NO2005014I1 (no) 2005-06-06

Similar Documents

Publication Publication Date Title
BR122012014331A2 (OSRAM)
BRPI9612258B1 (OSRAM)
BRPI9612138B1 (OSRAM)
FR05C0022I1 (OSRAM)
CH0741373H1 (OSRAM)
BR7501503U (OSRAM)
BR7502120U (OSRAM)
CN3031926S (OSRAM)
CN3032692S (OSRAM)
CN3029928S (OSRAM)
CN3030154S (OSRAM)
CN3030197S (OSRAM)
CN3030225S (OSRAM)
CN3030296S (OSRAM)
CN3030415S (OSRAM)
CN3030489S (OSRAM)
CN3030542S (OSRAM)
CN3030543S (OSRAM)
CN3030760S (OSRAM)
CN3031001S (OSRAM)
CN3031350S (OSRAM)
CN3031655S (OSRAM)
CN3031742S (OSRAM)
CN3034829S (OSRAM)
CN3032332S (OSRAM)